Rabies Diagnostics Market Report 2026

The rabies diagnostics market size has grown strongly in recent years. It will grow from $1.78 billion in 2025 to $1.89 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to high prevalence of rabies in animals, increasing awareness of rabies prevention, growth of veterinary diagnostic laboratories, government initiatives for rabies control, advancement in diagnostic reagents and kits.

The rabies diagnostics market size is expected to see strong growth in the next few years. It will grow to $2.45 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to adoption of ai-powered diagnostic tools, rising demand for rapid point-of-care tests, expansion of mobile-based disease surveillance, innovation in molecular and serology techniques, increasing public-private collaborations for rabies eradication. Major trends in the forecast period include rapid point-of-care rabies testing, advanced molecular diagnostic techniques, integration of ai in rabies detection, mobile-based rabies surveillance solutions, high-sensitivity serology testing.

The rising prevalence of rabies is expected to drive growth in the rabies diagnostics market. Rabies is a preventable viral disease most commonly transmitted through the bite of a rabid animal. The virus attacks the central nervous system of mammals, eventually causing brain damage and death. Rabies diagnostics are used to detect the presence of the rabies virus in humans and animals through various tests and techniques. Additionally, the increasing incidence of infectious diseases transmitted by animals has further boosted demand for rabies diagnostics. For example, in April 2024, according to the South Dakota Department of Health (SD DOH), a US-based government agency, South Dakota reported 20 animals testing positive for rabies in 2023, representing a 122% increase compared with 9 cases in 2022. Among the rabid animals, one was a domestic animal (a cow) and the remaining 19 were wild animals, including 18 bats and 1 skunk. Therefore, the growing prevalence of rabies is expected to propel the rabies diagnostics market.

Leading players in the rabies diagnostics market are developing innovative products, such as rabies antibody test kits, to maintain their market position. Rabies antibody test kits are diagnostic tools that detect antibodies in the blood to evaluate immunity or the need for additional rabies vaccination. For example, in February 2024, BioStone Animal Health, a US-based diagnostic company, launched AsurDx. The kit detects antibodies specific to the rabies virus in mammalian serum using a rapid and sensitive ELISA method. It provides a cost-effective solution for assessing rabies immunity in both vaccinated animals and those at risk. The kit is user-friendly, delivers reliable results, and ensures animals meet the standard of 0.5 international units (IU) per ml for protective immunity against rabies.

In November 2025, Zoetis Inc., a US-based provider of animal health medicines, vaccines, and veterinary diagnostic services, acquired Veterinary Pathology Group (VPG) for an undisclosed amount. Through this acquisition, Zoetis expanded its veterinary diagnostics capabilities in the United Kingdom and Ireland, enhancing its laboratory services, including rabies and other infectious disease testing, and improving its ability to deliver faster and more accurate diagnostic insights to veterinary professionals. Veterinary Pathology Group is a UK-based provider of multi-specialty veterinary diagnostic laboratory services, offering a wide range of tests to support clinical decision-making in animal health, including those relevant to rabies surveillance and diagnosis.

Major companies operating in the rabies diagnostics market are Bio-Rad Laboratories Inc., The Merck Group, Aviva Systems Biology Corporation, Creative Diagnostics, Demeditec Diagnostics GmbH, Abbexa Ltd., Norgen Biotek Corp., BioNote Inc., Express Biotech International Inc., MyBioSource Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Fluidigm Corp., Bio-X Diagnostics S.A., Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Heska Corporation, IDEXX Laboratories Inc., InBios International Inc., KHB Shanghai Kehua Bio-Engineering Co. Ltd., Meridian Bioscience Inc., MP Biomedicals LLC, Neogen Corporation, Randox Laboratories Ltd., SDIX LLC, Sigma-Aldrich Corporation.

North America was the largest region in the rabies diagnostics market in 2025. The regions covered in the rabies diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rabies diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the rabies diagnostics market by increasing the cost of imported diagnostic kits, reagents, and molecular testing equipment, creating supply chain bottlenecks for PCR, ELISA, and fluorescent antibody test components. Regions like North America and Europe, which rely on imported precision diagnostic tools, are most impacted, particularly in hospital and diagnostic center segments. On the positive side, tariffs encourage local manufacturing and development of cost-effective diagnostic solutions, boosting regional production capabilities.

The rabies diagnostics market research report is one of a series of new reports that provides rabies diagnostics market statistics, including rabies diagnostics industry global market size, regional shares, competitors with a rabies diagnostics market share, detailed rabies diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the rabies diagnostics industry. This rabies diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rabies diagnostics involve identifying the Rabies disease based on observed conditions and symptoms. This preventable viral illness is commonly transmitted through the bite of a rabid animal. Diagnosis of Rabies typically involves locating the rabies virus within any part of the infected animal's brain. In humans, diagnosis includes testing saliva, serum, spinal fluid, and skin biopsies from hair follicles at the back of the neck.

The methods employed in Rabies diagnostics encompass various tests such as fluorescent antibody tests, immunohistochemical tests, amplification methods, histologic examinations, and serology tests. The fluorescent antibody test (FA) is based on detecting rabies virus proteins (antigen) in the tissues of infected animals. Technologies utilized include ELISA/immunohistochemistry, chromatography techniques, PCR, and others. These diagnostics are commonly employed by hospitals, diagnostic centers, cancer palliative care clinics, and diverse end-users, including pharmacies.

The rabies diagnostics market includes revenues earned by entities by providing diagnostic services such as reverse transcription followed by polymerase chain reaction (RT-PCR), virus isolation, and direct fluorescent antibody (DFA) tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.